Skip to main content
Advertisement
Advertisement
SLS
SLS logo
SELLAS Life Sciences Group, Inc. Common Stock
7.47
USD
Sponsored
-0.39
-4.96%
Nov 16, 16:00 UTC -5
Closed
exchange

Pre-Market

26.69

+19.22
+257.32%

SELLAS Life Sciences Group, Inc. Common Stock (SLS) Earnings

SLS Earnings Reports

Positive Surprise Ratio

SLS beat 19 of 42 last estimates.

45%

Next Report

Date of Next Report
Mar 17, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/
-$0.05
Implied change from Q3 26 (Revenue/ EPS)
--
/
--
Implied change from Q4 25 (Revenue/ EPS)
--
/
--

SELLAS Life Sciences Group, Inc. Common Stock earnings per share and revenue

On Nov 12, 2026, SLS reported earnings of -0.05 USD per share (EPS) for Q3 26, beating the estimate of -0.05 USD, resulting in a 0.99% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a -2.12% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.05 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Enanta Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q4 26
Estimate
-$0.79
Actual
-$0.81
Surprise
-1.38%
logo
Invivyd, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.10
Surprise
+26.47%
logo
ALX Oncology Holdings Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.15
Surprise
-6.31%
logo
Neumora Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.18
Surprise
+10.54%
logo
Rein Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
logo
LeonaBio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.73
Actual
-$0.89
Surprise
-20.35%
logo
Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%
logo
Dare Bioscience, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.26
Actual
-$0.18
Surprise
+32.13%
logo
Pulmatrix, Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-
Actual
-$0.34
Surprise
-
logo
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%
FAQ
For Q3 2026, SELLAS Life Sciences Group, Inc. Common Stock reported EPS of -$0.05, beating estimates by 0.99%, and revenue of --, -- -- expectations.
The stock price moved down -2.12%, changed from $8.03 before the earnings release to $7.86 the day after.
The next earning report is scheduled for Mar 17, 2027.
Based on -- analysts, SELLAS Life Sciences Group, Inc. Common Stock is expected to report EPS of -$0.05 and revenue of -- for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement